Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Xilio Therapeutics (XLO – Research Report) and keeping the price target at $5.00.
Michael Ulz has given his Buy rating due to a combination of factors related to Xilio Therapeutics’ ongoing clinical developments and financial outlook. The company’s progress with its lead candidate, vilastobart, is particularly promising. The updated Phase 2 data for vilastobart, expected in mid-2025, builds on encouraging initial results, especially in patients without liver metastases, where the objective response rate surpassed internal benchmarks. Additionally, the manageable safety profile with limited severe adverse events adds to the optimism about vilastobart’s potential.
Furthermore, the ongoing dose escalation studies for XTX301, another promising candidate, indicate a robust pipeline. The financial health of Xilio Therapeutics is also a positive factor, with sufficient cash reserves and expected collaboration payments from Abbvie to support operations into early 2026. These elements combined suggest a favorable outlook for the company’s stock, justifying the Buy rating.
According to TipRanks, Ulz is an analyst with an average return of -5.7% and a 34.17% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Alnylam Pharma, and Sarepta Therapeutics.